Epidemiology, prevention, and early detection of breast cancer

Current Opinion in Oncology

Volumn 11, Issue 6, 1999, Pages 435-441

  Alberg, Anthony J ^a   Lam, Anthony P ^a   Helzlsouer, Kathy J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANOCHLORINE DERIVATIVE; POLYCHLORINATED BIPHENYL; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; EARLY DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION; HUMAN; MALE; MAMMOGRAPHY; MASTECTOMY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 0032750167     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199911000-00003     Document Type: Review

References (102)

1. 1 Parkin DM, Pisani P, Fertay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999, 80:827-841.
2. 2 Parkin DM: The global burden of cancer. Cancer Biol 1998, 8:219-235.
3. 3 American Cancer Society: Cancer facts and figures-1999. Atlanta, GA: American Cancer Society; 1999.
4. 4 Wingo PA, Ries LAG, Parker SL, Heath CW Jr: Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998, 7:271-282.
5. 5 Goss PE, Reid C, Pintilie M, Lim R, Miller N: Male breast carcinoma. Cancer 1999, 85:629-639.
6. 6 Hsing AW, McLaughlin JK, Cocco P, Chien HTC, Fraumeni JF Jr: Risk factors for male breast cancer. Cancer Causes Control 1998, 9:269-275.
7. 7 Rosenblatt KA, Thomas DB, Jimenez LM, Fish B, McTiernan A, Stalsberg H, et al.: The relationship between diet and breast cancer in men (United States). Cancer Causes Control 1999, 10: 107-113.
8. 8 Sørensen JT, Friis S, Olsen JH, Thulstrup AM, Mellemjkær L, Linet M, et al.: Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol 1998, 93:231-233.
9. 9 Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B, Olah E: High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999, 59:995-998.
10. 10 Wohlfahrt J, Melbye M: Maternal risk of breast cancer and birth characteristics of offspring by time since birth. Epidemiology 1999, 10:441-444.
11. 11 Verkasalo PK, Kaprio J, Pukkala E, Koskenvuo M: Breast cancer risk in monozygotic and dizygotic female twins: a 20-year population-based cohort study in Finland from 1976-1995. Cancer Epidemiol Biomarkers Prev 1999, 8:271-274.
12. 12 Lipworth L, Hsieh C-C, Wide L, Ekbom A, Yu S-Z, Yu G-Z, et al.: Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer. Br J Cancer 1999, 79:7-12.
13. 13 Garland M, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Spiegelman D, et al.: Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of U.S. women. Am J Epidemiol 1998, 147:636-643.
14. 14 Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergström R, Adami H-O: The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer 1999, 80:231-236.
15. 15 Titus-Ernstoff L, Longnecker MP, Newcomb PA, Dain B, Greenberg ER, Mittendorf R, et al.: Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998, 7:783-789.
16. 16 Cold S, Hansen S, Overvad K, Rose C: A woman's build and the risk of breast cancer. Eur J Cancer 1998, 34:1163-1174.
17. 17 Magnusson C, Baron J, Persson I, Wolk A, Bergström R, Trichopoulos D, Adami H-O: Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer 1998, 76:29-34.
18. 18 Chie W-C, Li C-Y, Huang C-S, Chang K-J, Lin R-S: Body size as a factor in different ages and breast cancer risk in Taiwan. Anticancer Res 1998, 18:565-570.
19. 19 Peacock SL, White E, Daling JR, Voigt LF, Malone KE: Relation between obesity and breast cancer in young women. Am J Epidemiol 1999, 149:339-346.
20. 20 Kaaks R, Van Noord PAH, Tonkelaar ID, Peeters PHM, Riboli E, Grobbee DE: Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch "DOM" Cohort. Int J Cancer 1998, 76:647-651.
21. 21 Egan KM, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Baron JA, Willett WC, Stampfer MJ, Trichopoulos D: The relation of breast size to breast cancer risk in postmenopausal women (United States). Cancer Causes Control 1999, 10:115-118.
22. 22 Greenwald P: Role of dietary fat in the causation of breast cancer: point. Cancer Epidemiol Biomarkers Prev 1999, 8:3-7.
23. 23 Hunter DJ: Role of dietary fat in the causation of breast cancer: counterpoint. Cancer Epidemiol Biomarkers Prev 1999, 8:9-13.
24. 24 Boyd NF, Martin L, Lockwood G, Greenberg C, Yaffe M, Tritchler D: Diet and breast cancer. Nutrition 1998, 14:722-724.
25. 25 Wu AH, Pike MC, Stram DO: Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999, 91:529-534.
26. 26 Knight JA, Martin LJ, Greenberg CV, Lockwood GA, Byng JW, Yaffe MJ, et al.: Macronutrient intake and change in mammographic density at menopause: results from a randomized trial. Cancer Epidemiol Biomarkers Prev 1999, 8:123-128.
27. 27 Stoll BA: Breast cancer and the western diet: role of fatty acids and antioxidant vitamins. Eur J Cancer 1998, 34:1852-1856.
28. 28 Holmes MD, Hunter DJ, Colditz GA, Stampfer MJ, Hankinson SE, Speizer FE, et al.: Association of dietary intake of fat and fatty acids with risk of breast cancer. JAMA 1999, 281:914-920.
29. 29 Franceschi S, Parpinel M, La Vecchia C, Favero A, Talamini R, Negri E: Role of different types of vegetables and fruit in the prevention of cancer of the colon, rectum, and breast. Epidemiology 1998, 9:338-341.
30. 30 Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, et al.: Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst 1999, 91:547-556.
31. 31 Bohlke K, Spiegelman D, Trichopoulou A, Katsouyanni K, D Trichopoulos: Vitamins A, C and E and the risk of breast cancer: results from a case-control study in Greece. Br J Cancer 1999, 79:23-29.
32. 32 Jumaan AO, Holmberg L, Zack M, Mokdad AH, Ohlander EM, Wolk A, Byers T: Beta-carotene intake and risk of postmenopausal breast cancer. Epidemiology 1999, 10:49-53.
33. 33 Wu K, Helzlsouer KJ, Comstock GW, Hoffman SC, Nadeau MR, Selhub J: A prospective study on folate, B12, and pyridoxal 5'-phosphate (B6) and breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:209-217.
34. 34 John EM, Schwartz GG, Dreon DM, Koo J: Vitamin D and breast cancer risk: the NHANES I epidemiolgic follow-up study, 1971-1975 to 1992. Cancer Epidemiol Biomarkers Prev 1999, 8:399-406.
35. 35 Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Orentreqich N: Prediagnostic serum vitamin D and breast cancer, J Natl Cancer Inst 1998, 461-463.
36. 36 Levi F, Pasche C, Lucchini F, La Vecchia C: Occupational and leisure time physical activity and the risk of breast cancer. Eur J Cancer 1999, 35:775-778.
37. 37 Rockhill B, Willett WC, Hunter DJ, Manson JE, Hankinson SE, Spiegelman D, Colditz GA: Physical activity and breast cancer risk in a cohort of young women. J Natl Cancer Inst 1998, 90:1155-1160.
38. 38 Gram IT, Funkhouser E, Tabar L: Moderate physical activity in relation to mammographic patterns. Cancer Epidemiol Biomarkers Prev 1999, 8:117-122.
39. 39 Colditz GA: Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998, 90:814-823,
40. 40 Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, et al.: Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999, 130:262-269.
41. 41 Holli K, Isola J, Cuzick J: Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 1998, 16:3115-3120.
42. 42 O'Connor IF, Shembekar MV, Shousha S: Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 1998, 51:935-938.
43. 43 Gapstur SM, Morrow M, Sellers TA: Hormone replacement therapy and risk of breast cancer with a favorable histology. JAMA 1999, 281:2091-2097.
44. 44 Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI: Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998, 51:1277-1283.
45. 45 Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN: Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999, 91:264-270.
46. 46 Chlebowski RT, McTiernan A: Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 1999, 17:130-142.
47. 47 Dupont WD, Page DL, Parl FF, Plummer WD, Schuyler PA, Kasami M, Jensen RA: Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999, 85: 1277-1283.
48. 48 Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999, 130:270-277.
49. 49 Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope CC, et al.: Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999, 91:629-634.
50. 50 Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al.: Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998, 351:1393-1396.
51. 51 Urskin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC: Urinary 2-hydroxyestrone/16α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999, 91:1067-1072.
52. 52 Dorgan JF, Brock JW, Rothman N, Needham LL, Miller R, Stephenson HE Jr, et al.: Serum organochlorine pesticides and PCBs and breast cancer risk: results from a prospective analysis. Cancer Causes Control 1999, 10:1-11.
53. 53 Helzlsouer KJ, Alberg AJ, Huang H-Y, Hoffman SC, Strickland PT, Brock JW, et al.: Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:525-532.
54. 54 Høyer AP, Grandjean P, Jørgensen T, Brock JW, Hartvig HB: Organochlorine exposure and risk of breast cancer. Lancet 1998, 352:1816-1820.
55. 55 Zheng T, Holford TR, Mayne ST, Tessari J, Owens PH, Zahm SH, et al.: Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. Cancer Epidemiol Biomarker Prev 1999, 8:407-411.
56. 56 Zheng T, Holford TR, Mayne ST, Owens PH, Ward B, Carter D. et al.: B-Benzene hexachloride in breast adipose tissue and risk of breast carcinoma. Cancer 1999, 85:2212-2218.
57. 57 Moysich KB, Shields PG, Freudenheim JL, Schisterman EF, Vena JE, Kostyniak P, et al.: Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarker Prev 1999, 8:41-44.
58. 58 Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ: Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998, 7:1133-144.
59. 59 Salminen TM, Saarenmaa IE, Heikkila MM, Hakama M: Risk of breast cancer and changes in mammographic parenchymal patterns over time. Acta Oncologica 1998, 37: 547-551.
60. 60 van Gils CH, Otten JDM, Verbeek ALM, Hendriks JHCL, Holland R: Effect of mammographic breast density on breast cancer screening performance. J Epidemiol Community Health 1998, 52: 267-271.
61. 61 Hemminki K, Vaittinen P: Familial risks in second primary breast cancer based on a family cancer database. Eur J Cancer 1999, 35:455-458.
62. 62 Olsen JH, Seersholm N, Boice JD Jr, Kjaer SK, Fraumeni JF Jr: Cancer risk in close relatives of women with early-onset breast cancer-a population-based incidence study. Br J Cancer 1999, 79:673-679.
63. 63 Hemminki K, Vaittinen P: Familial breast cancer in the family-cancer database. Int J Cancer 1998, 77:386-391.
64. 64 Sellers TA, Walsh AJ, Grabrick DM, Anderson KE, Cerhan JR, Folsom AR: Family history, ethnicity, and relative risk of breast cancer in prospective cohort study of older women. Cancer Epidemiol Biomarkers Prev 1999, 8:421-425.
65. 65 Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al.: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999, 91:943-949.
66. 66 Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King M-C: Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998, 279:915-921.
67. 67 Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA: BRCA-1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 with first degree family history. JAMA 1998, 279:922-929.
68. 68 Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, et al.: Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:259-263.
69. 69 Pharoah PDP, Easton DF, Stockton DL, Gayther S, Ponder BAJ: Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res 1999, 59:868-871.
70. 70 Lipkus IM, Iden D, Terrenoire J, Feaganes JR: Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:533-539.
71. 71 Raffel L: Genetic counseling and genetic testing for cancer risk assessment, Clin Obstet Gynecol 1998, 41:141-156.
72. 72 Eisinger F, Geller G, Burke W, Holtzmann NA: Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet 1999, 353:919-920.
73. 73 Eisen A, Weber BL: Prophylactic mastectomy - the price of fear. N Engl J Med 1999, 340:137-138.
74. 74 Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77-84. A retrospective cohort study provides valuable information by quantifying the reduction in risk associated with prophylactic mastectomy.
75. 75 Helzlsouer KJ, Huang H-Y, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA: Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 1998, 7:945-949.
76. 76 Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, et al.: The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999, 59:1015-1020.
77. 77 Gertig DM, Hankinson SE, Hough H, Spiegelman D, Colditz GA, Willett WC, et al.: N-Acetyl transferase 2 genotypes, meat intake and breast cancer risk. Int J Cancer 1999, 80:13-17.
78. 78 Zheng W, Dietz AC, Campbell DR, Wen W-Q, Cerhan JR, Sellers TA, et al.: N-Acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:233-239.
79. 79 Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388. A double-blind, placebo-controlled randomized trial of 13,388 U.S. women at high risk of breast cancer, which demonstrated a strong reduction in incidence of breast cancer among women randomized to the tamoxifen group (22.0 cases/1000) compared with the placebo group (43.4 cases/1000).
80. 80 Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98-101. A double-blind, placebo-controlled randomized trial of 2,494 U.K. women between the ages of 30 and 70 years and who had a positive family history of breast cancer. There was no evidence of a reduced incidence of breast cancer among women randomized to the tamoxifen group compared with the placebo group.
81. 81 Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998, 352:93-97. A double-blind, placebo-controlled randomized trial of 5,408 Italian women who had a hysterectomy. No significant difference in the incidence of breast cancer was observed between the tamoxifen and placebo groups.
82. 82 Pritchard KI: Is tamoxifen effective in prevention of breast cancer? Lancet 1998, 352:80-81.
83. 83 Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999, 281:2189-2197. A randomized, placebo-controlled trial of 7,705 postmenopausal women who are likely at low risk of breast cancer demonstrated a striking protective effect of raloxifene in preventing the occurrence of breast cancer.
84. 84 American Cancer Society: Cancer facts and figures for African Americans 1998-1999. Atlanta, GA: American Cancer Society; 1999.
85. 85 McCarthy EP, Burns RB, Coughlin SS, Freund KM, Rice J, Marwill SL, et al.: Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 1998, 128:729-736.
86. 86 Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS: Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA 1998, 279:1801-1807. An important cancer control study that used a case-control study design to look beyond "race" to find out what accounted for racial differences in late-stage presentation.
87. 87 Slater JS, Ha CN, Malone ME, McGovern P, Madigan SD, Finnegan JR, et al.: A randomized community trial to increase mammography utilization among low-income women living in public housing. Prev Med 1998, 27:862-870.
88. 88 Lauver DR, Kane J: A motivational message, external barriers, and mammography utilization. Cancer Detect Prev 1999, 23:254-264.
89. 89 Elwood M, McNoe B, Smith T, Bandaranayake M, Doyle TCA: Once is enough - why some women do not continue to participate in a breast cancer screening programme. NZ Med J 1998, 111:180-183.
90. 90 Song L, Fletcher R: Breast cancer rescreening in low-income women. Am J Prev Med 1998, 15:128-133.
91. 91 Solomon LJ, Mickey RM, Rairikar CJ, Worden JK, Flynn BS: Three-year prospective adherence to three breast cancer screening modalities. Prev Med 1998, 27:781-786.
92. 92 Partin MR, Casey-Paal AL, Slater JS, Korn JE: Measuring mammography compliance: lessons learned from a survival analysis of screening behavior. Cancer Epidemiol Biomarkers Prev 1998, 7:681-687.
93. 93 Kopans D: The breast cancer screening controversy and the National Institutes of Health consensus development conference on breast cancer screening for women ages 40-49. Radiology 1999, 210:4-9.
94. 94 Dickersin K: Breast screening in women aged 40-49 years: what next? Lancet 1999, 353:1896-1902.
95. 95 Napoli M: What do women want to know? Monogr Natl Cancer Inst 1997, 22:11-13.
96. 96 Gail M, Rimer B: Risk-based recommendations for mammographic screening for women in their forties. J Clin Oncol 1998, 16:3105-3113.
97. 97 Lalloo F, Boggis CRM, Evans DGR, Shenton A, Threlfall AG, Howell A: Screening by mammography, women with a family history of breast cancer. Eur J Cancer 1998, 34:937-940.
98. 98 Kollias J, Sibbering DM, Blamey RW, Holland PAM, Obuszko Z, Wilson ARM, et al.: Screening women aged less than 50 years with a family history of breast cancer. Eur J Cancer 1998, 43:878-883.
99. 99 Smith-Bindman R, Kerlikowske K: Is there a downside to elderly women undergoing screening mammography? J Natl Cancer Inst 1998, 90:1322-1323.
100. 100 Burack RC, Gurney JG, McDaniel AM: Health status and mammography use among older women. J Gen Intern Med 1998, 13:366-372.
101. 101 Kiefe CI, Funkhouser E, Fouad MN, May DS: Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med 1998, 13:357-365.
102. 102 Welch HG, Fisher ES: Diagnostic testing following screening mammography in the elderly. J Natl Cancer Inst 1998, 90:1389-1392.